Top

BMC Neurology

Published in:

Open Access 01-12-2024 | Parkinson's Disease | Research

Associations of sleep disorders with serum neurofilament light chain levels in Parkinson’s disease

Authors: Wan-Yi Qi, Yan Sun, Yun Guo, Lan Tan

Published in: BMC Neurology | Issue 1/2024

Abstract

Background

Sleep disorders are a prevalent non-motor symptom of Parkinson’s disease (PD), although reliable biological markers are presently lacking.

Objectives

To explore the associations between sleep disorders and serum neurofilament light chain (NfL) levels in individuals with prodromal and early PD.

Methods

The study contained 1113 participants, including 585 early PD individuals, 353 prodromal PD individuals, and 175 healthy controls (HCs). The correlations between sleep disorders (including rapid eye movement sleep behavior disorder (RBD) and excessive daytime sleepiness (EDS)) and serum NfL levels were researched using multiple linear regression models and linear mixed-effects models. We further investigated the correlations between the rates of changes in daytime sleepiness and serum NfL levels using multiple linear regression models.

Results

In baseline analysis, early and prodromal PD individuals who manifested specific behaviors of RBD showed significantly higher levels of serum NfL. Specifically, early PD individuals who experienced nocturnal dream behaviors (β = 0.033; P = 0.042) and movements of arms or legs during sleep (β = 0.027; P = 0.049) showed significantly higher serum NfL levels. For prodromal PD individuals, serum NfL levels were significantly higher in individuals suffering from disturbed sleep (β = 0.038; P = 0.026). Our longitudinal findings support these baseline associations. Serum NfL levels showed an upward trend in early PD individuals who had a higher total RBDSQ score (β = 0.002; P = 0.011) or who were considered as probable RBD (β = 0.012; P = 0.009) or who exhibited behaviors on several sub-items of the RBDSQ. In addition, early PD individuals who had a high total ESS score (β = 0.001; P = 0.012) or who were regarded to have EDS (β = 0.013; P = 0.007) or who exhibited daytime sleepiness in several conditions had a trend toward higher serum NfL levels.

Conclusion

Sleep disorders correlate with higher serum NfL, suggesting a link to PD neuronal damage. Early identification of sleep disorders and NfL monitoring are pivotal in detecting at-risk PD patients promptly, allowing for timely intervention. Regular monitoring of NfL levels holds promise for tracking both sleep disorders and disease progression, potentially emerging as a biomarker for evaluating treatment outcomes.

Available only for authorised users

Marinus J, Zhu K, Marras C, Aarsland D, van Hilten JJ. Risk factors for non-motor symptoms in Parkinson’s disease. Lancet Neurol. 2018;17 6:559–68. https://doi.org/10.1016/S1474-4422(18)30127-3.CrossRef

Xu Z, Anderson KN, Pavese N. Longitudinal studies of Sleep disturbances in Parkinson’s Disease. Curr Neurol Neurosci Rep. 2022;22 10:635–55. https://doi.org/10.1007/s11910-022-01223-5.CrossRef

Miglis MG, Adler CH, Antelmi E, Arnaldi D, Baldelli L, Boeve BF, et al. Biomarkers of conversion to alpha-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol. 2021;20 8:671–84. https://doi.org/10.1016/S1474-4422(21)00176-9.CrossRef

Shen Y, Huang JY, Li J, Liu CF. Excessive daytime sleepiness in Parkinson’s Disease: clinical implications and management. Chin Med J (Engl). 2018;131 8:974–81. https://doi.org/10.4103/0366-6999.229889.CrossRef

Meindorfner C, Korner Y, Moller JC, Stiasny-Kolster K, Oertel WH, Kruger HP. Driving in Parkinson’s disease: mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord. 2005;20 7:832–42. https://doi.org/10.1002/mds.20412.CrossRef

Perez-Carbonell L, Mignot E, Leschziner G, Dauvilliers Y. Understanding and approaching excessive daytime sleepiness. Lancet. 2022;400 10357:1033–46. https://doi.org/10.1016/S0140-6736(22)01018-2.CrossRef

Jadidi A, Rezaei Ashtiani A, Khanmohamadi Hezaveh A, Aghaepour SM. Therapeutic effects of magnesium and vitamin B6 in alleviating the symptoms of restless legs syndrome: a randomized controlled clinical trial. BMC Complement Med Ther. 2022;23(1). https://doi.org/10.1186/s12906-022-03814-8.

Backstrom D, Linder J, Jakobson Mo S, Riklund K, Zetterberg H, Blennow K, et al. NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology. 2020;95 7:e827–38. https://doi.org/10.1212/WNL.0000000000010084.CrossRef

Lin CH, Li CH, Yang KC, Lin FJ, Wu CC, Chieh JJ, et al. Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology. 2019;93 11:e1104–11. https://doi.org/10.1212/WNL.0000000000008088.CrossRef

10.

Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88 10:930–7. https://doi.org/10.1212/WNL.0000000000003680.CrossRef

11.

Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, et al. The Parkinson’s progression markers initiative (PPMI) - establishing a PD biomarker cohort. Ann Clin Transl Neurol. 2018;5 12:1460–77. https://doi.org/10.1002/acn3.644.CrossRef

12.

Parkinson Progression Marker I. The Parkinson Progression Marker Initiative (PPMI). 4:629 – 35. Prog Neurobiol. 2011;95. https://doi.org/10.1016/j.pneurobio.2011.09.005.

13.

Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire–a new diagnostic instrument. Mov Disord. 2007;22 16:2386–93. https://doi.org/10.1002/mds.21740.CrossRef

14.

Nomura T, Inoue Y, Kagimura T, Uemura Y, Nakashima K. Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson’s disease patients. Sleep Med. 2011;12 7:711–3. https://doi.org/10.1016/j.sleep.2011.01.015.CrossRef

15.

Simuni T, Caspell-Garcia C, Coffey C, Chahine LM, Lasch S, Oertel WH, et al. Correlates of excessive daytime sleepiness in de novo Parkinson’s disease: a case control study. Mov Disord. 2015;30 10:1371–81. https://doi.org/10.1002/mds.26248.CrossRef

16.

Wang XT, Yu H, Liu FT, Zhang C, Ma YH, Wang J, et al. Associations of sleep disorders with cerebrospinal fluid alpha-synuclein in prodromal and early Parkinson’s disease. J Neurol. 2022;269 5:2469–78. https://doi.org/10.1007/s00415-021-10812-2.CrossRef

17.

Sampedro F, Perez-Gonzalez R, Martinez-Horta S, Marin-Lahoz J, Pagonabarraga J, Kulisevsky J. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson’s disease. Parkinsonism Relat Disord. 2020;74:43–9. https://doi.org/10.1016/j.parkreldis.2020.04.009.CrossRefPubMed

18.

Soylu-Kucharz R, Sandelius A, Sjogren M, Blennow K, Wild EJ, Zetterberg H, et al. Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice. Sci Rep. 2017;7(1:14114). https://doi.org/10.1038/s41598-017-14179-1.

19.

Ma LZ, Zhang C, Wang H, Ma YH, Shen XN, Wang J, et al. Serum Neurofilament Dynamics predicts cognitive progression in de novo Parkinson’s Disease. J Parkinsons Dis. 2021;11 3:1117–27. https://doi.org/10.3233/JPD-212535.CrossRef

20.

McKenna D, Peever J. Degeneration of rapid eye movement sleep circuitry underlies rapid eye movement sleep behavior disorder. Mov Disord. 2017;32 5:636–44. https://doi.org/10.1002/mds.27003.CrossRef

21.

Peever J, Luppi PH, Montplaisir J. Breakdown in REM sleep circuitry underlies REM sleep behavior disorder. Trends Neurosci. 2014;37 5:279–88. https://doi.org/10.1016/j.tins.2014.02.009.CrossRef

22.

Carvalho DZ, St Louis EK, Boeve BF, Mielke MM, Przybelski SA, Knopman DS, et al. Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. Sleep Med. 2017;32:236–43. https://doi.org/10.1016/j.sleep.2016.08.023.CrossRefPubMed

23.

Postuma RB, Adler CH, Dugger BN, Hentz JG, Shill HA, Driver-Dunckley E, et al. REM sleep behavior disorder and neuropathology in Parkinson’s disease. Mov Disord. 2015;30 10:1413–7. https://doi.org/10.1002/mds.26347.CrossRef

24.

Hu Y, Yu SY, Zuo LJ, Cao CJ, Wang F, Chen ZJ, et al. Parkinson disease with REM sleep behavior disorder: features, alpha-synuclein, and inflammation. Neurology. 2015;84 9:888–94. https://doi.org/10.1212/WNL.0000000000001308.CrossRef

25.

Teng X, Mao S, Wu H, Shao Q, Zu J, Zhang W, et al. The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson’s disease. J Neurochem. 2023;165(2):268–76. https://doi.org/10.1111/jnc.15780.CrossRefPubMed

26.

Zhu Y, Yang B, Wang F, Liu B, Li K, Yin K, et al. Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson’s disease. J Neuroimmunol. 2021;358:577662. https://doi.org/10.1016/j.jneuroim.2021.577662.CrossRefPubMed

27.

Park DG, Kim JW, An YS, Chang J, Yoon JH. Plasma neurofilament light chain level and orthostatic hypotension in early Parkinson’s disease. J Neural Transm (Vienna). 2021;128 12:1853–61. https://doi.org/10.1007/s00702-021-02423-y.CrossRef

28.

Khalil M, Pirpamer L, Hofer E, Voortman MM, Barro C, Leppert D, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun. 2020;11(1:812). https://doi.org/10.1038/s41467-020-14612-6.

29.

Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005;233(1–2):183–98. https://doi.org/10.1016/j.jns.2005.03.015.CrossRefPubMed

30.

Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14 10:577–89. https://doi.org/10.1038/s41582-018-0058-z.CrossRef

31.

Zhang P, Tan CW, Chen GH, Ge YJ, Xu J, Xia L, et al. Patients with chronic insomnia disorder have increased serum levels of neurofilaments, neuron-specific enolase and S100B: does organic brain damage exist? Sleep Med. 2018;48:163–71. https://doi.org/10.1016/j.sleep.2017.12.012.CrossRefPubMed

32.

Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342 6156:373–7. https://doi.org/10.1126/science.1241224.CrossRef

33.

Sundaram S, Hughes RL, Peterson E, Muller-Oehring EM, Bronte-Stewart HM, Poston KL, et al. Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson’s disease. Neurosci Biobehav Rev. 2019;103:305–15. https://doi.org/10.1016/j.neubiorev.2019.05.016.CrossRefPubMedPubMedCentral

34.

Benveniste H, Lee H, Volkow ND. The glymphatic pathway: Waste removal from the CNS via Cerebrospinal Fluid Transport. Neuroscientist. 2017;23 5:454–65. https://doi.org/10.1177/1073858417691030.CrossRef

35.

Nilsson C, Stahlberg F, Thomsen C, Henriksen O, Herning M, Owman C. Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging. Am J Physiol. 1992;262(1 Pt 2):R20–4. https://doi.org/10.1152/ajpregu.1992.262.1.R20.CrossRefPubMed

36.

Abbott RD, Ross GW, Duda JE, Shin C, Uyehara-Lock JH, Masaki KH, et al. Excessive daytime sleepiness and topographic expansion of Lewy pathology. Neurology. 2019;93 15:e1425–32. https://doi.org/10.1212/WNL.0000000000008241.CrossRef

37.

Abbott RD, Ross GW, White LR, Tanner CM, Masaki KH, Nelson JS, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology. 2005;65 9:1442–6. https://doi.org/10.1212/01.wnl.0000183056.89590.0d.CrossRef

38.

Kyriacou CP, Hastings MH. Circadian clocks: genes, sleep, and cognition. Trends Cogn Sci. 2010;14 6:259–67. https://doi.org/10.1016/j.tics.2010.03.007.CrossRef

39.

Carvalho DZ, St Louis EK, Przybelski SA, Morgenthaler TI, Machulda MM, Boeve BF, et al. Sleepiness in cognitively unimpaired older adults is Associated with CSF biomarkers of inflammation and Axonal Integrity. Front Aging Neurosci. 2022;14:930315. https://doi.org/10.3389/fnagi.2022.930315.CrossRefPubMedPubMedCentral

40.

Lim AS, Fleischman DA, Dawe RJ, Yu L, Arfanakis K, Buchman AS, et al. Regional Neocortical Gray Matter structure and sleep fragmentation in older adults. Sleep. 2016;39(1):227–35. https://doi.org/10.5665/sleep.5354.CrossRefPubMedPubMedCentral

41.

Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Vemuri P, Skoog I, et al. Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology. 2019;93(3):e252–60. https://doi.org/10.1212/WNL.0000000000007767.CrossRefPubMedPubMedCentral

42.

Seneviratne U, Puvanendran K. Excessive daytime sleepiness in obstructive sleep apnea: prevalence, severity, and predictors. Sleep Med. 2004;5 4:339–43. https://doi.org/10.1016/j.sleep.2004.01.021.CrossRef

43.

Yeh NC, Tien KJ, Yang CM, Wang JJ, Weng SF. Increased risk of Parkinson’s disease in patients with obstructive sleep apnea: a Population-Based, Propensity Score-Matched, Longitudinal Follow-Up study. Med (Baltim). 2016;95(2):e2293. https://doi.org/10.1097/MD.0000000000002293.CrossRef

44.

Arslan B, Semsi R, Iriz A, Sepici Dincel A. The evaluation of serum brain-derived neurotrophic factor and neurofilament light chain levels in patients with obstructive sleep apnea syndrome. Laryngoscope Investig Otolaryngol. 2021;6 6:1466–73. https://doi.org/10.1002/lio2.683.CrossRef

45.

Enroth S, Hallmans G, Grankvist K, Gyllensten U. Effects of Long-Term Storage Time and Original Sampling Month on Biobank plasma protein concentrations. EBioMedicine. 2016;12:309–14. https://doi.org/10.1016/j.ebiom.2016.08.038.CrossRefPubMedPubMedCentral

Title: Associations of sleep disorders with serum neurofilament light chain levels in Parkinson’s disease
Authors: Wan-Yi Qi
Yan Sun
Yun Guo
Lan Tan
Publication date: 01-12-2024
Publisher: BioMed Central
Keyword: Parkinson's Disease
Published in: BMC Neurology / Issue 1/2024
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-024-03642-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Associations of sleep disorders with serum neurofilament light chain levels in Parkinson’s disease

Abstract

Background

Objectives

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Association between cerebrospinal fluid pressure and cognition in patients with Alzheimer’s disease and Lewy body dementia

Feasibility of early radial artery occlusion recanalization and reuse through transradial access for neuroendovascular procedures

Efficacy of differential reinforcement of other behaviors therapy for tic disorder: a meta-analysis

Delivering the diagnosis of multiple system atrophy: a multicenter survey on Japanese neurologists’ perspectives

Brain frailty associated with stroke events in anterior circulation large artery occlusion

Arterial transit artifact as a short-term prognostic indicator in acute ischemic stroke